EnerVenue | $300,000,000 | (Apr 3, 2026)
Acurion, Inc. | $4,300,000 | (Apr 3, 2026)
Gander Robotics | $1,100,000 | (Apr 3, 2026)
MitoRx Therapeutics
United Kingdom
- Oxford, Oxfordshire
- 15/12/2023
- Seed
- $4,000,000
MitoRx Therapeutics is a pre-clinical stage rare disease biotech company aiming to become the leading global developer of medicines arresting the progression of degenerative diseases driven by mitochondrial dysfunction, with a focus on neuromuscular disease, metabolic disease and neurodegenerative disease.
- Industry Biotechnology Research
- Website https://www.mitorxtherapeutics.com/
- LinkedIn https://www.linkedin.com/company/mitorx-therapeutics/about/
Related People
Jon ReesFounder
United Kingdom -
Greater Oxford Area
Jon is an entrepreneurial, innovation and investment-focused life sciences PhD & tenacious leader with deep strategic insight. He can draw on a vast personal network within the investment and drug development industries. Jon founded his fourth company, MitoRx Therapeutics, in 2021.
Jon did his post-doc engineering primary metabolism at the University of Oxford, has a PhD in metabolic engineering from the Royal Holloway University of London, a Masters with Distinction from LJMU and a BSc from University of Manchester Institute for Science and Technology. May consider non-executive director positions.
daydream | $15,000,000 | (Apr 3, 2026)
Numos | $4,250,000 | (Apr 3, 2026)
Alien | $7,100,000 | (Apr 3, 2026)
Monarch Quantum | $55,000,000 | (Apr 3, 2026)
Sona(UK) | $45,000,000 | (Apr 2, 2026)
Linx Security | $50,000,000 | (Apr 2, 2026)
Earlyasset | $2,000,000 | (Apr 2, 2026)
Rowan(US) | $3,300,000 | (Apr 2, 2026)
Whirl AI | $8,900,000 | (Apr 2, 2026)